A phase I open-label study of Ad-RTS-hIL-12, an adenoviral vector engineered to express hIL-12 under the control of an oral activator ligand, in subjects with unresectable stage III/IV melanoma.
Gerald P. Linette
Consultant or Advisory Role - ZIOPHARM Oncology
Omid Hamid
Consultant or Advisory Role - ZIOPHARM Oncology
Research Funding - ZIOPHARM Oncology
Eric D. Whitman
No relevant relationships to disclose
John J. Nemunaitis
No relevant relationships to disclose
Jason Chesney
Research Funding - ZIOPHARM Oncology
Sanjiv S. Agarwala
No relevant relationships to disclose
Alexander Starodub
No relevant relationships to disclose
John A Barrett
Employment or Leadership Position - ZIOPHARM Oncology
Andrew Marsh
Employment or Leadership Position - ZIOPHARM Oncology
Stock Ownership - ZIOPHARM Oncology
Lori A. Martell
Employment or Leadership Position - ZIOPHARM Oncology
Angela Cho
Employment or Leadership Position - ZIOPHARM Oncology
Stock Ownership - ZIOPHARM Oncology
Thomas D. Reed
Employment or Leadership Position - Intrexon
Consultant or Advisory Role - Intrexon
Stock Ownership - Intrexon
Hagop Youssoufian
Employment or Leadership Position - ZIOPHARM Oncology
Consultant or Advisory Role - Intrexon
Stock Ownership - ZIOPHARM Oncology
Andrea Vergara-Silva
Employment or Leadership Position - ZIOPHARM Oncology